PhaseBio Pharmaceuticals, Inc. (PHAS)
EBITDA Margin
3443.23%
TTM · Period ending:
PHAS EBITDA Margin
Latest reported3443.23%period ending
Latest reported3443.23%period ending
PHAS EBITDA Margin (0.00% → 3443.23%)
Annual ebitda margin
High-resolution chart · PNG
PHAS ebitda margin history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Margin |
|---|---|
| 15,350.217% | |
| -30,191.25% | |
| -1,609.3604% | |
| -2,966.6168% | |
| 0% | |
| 0% |